Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

86.16EUR
3 Mar 2015
Change (% chg)

-- (--)
Prev Close
€86.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,419,536
52-wk High
€89.95
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.64
Market Cap(Mil.): €113,993.30
Shares Outstanding(Mil.): 1,319.37
Dividend: 2.85
Yield (%): 3.30

Financials

  SASY.PA Industry Sector
P/E (TTM): 25.99 39.43 40.59
EPS (TTM): 3.32 -- --
ROI: 5.49 16.96 16.27
ROE: 7.77 17.47 17.23
Search Stocks

Sacked Sanofi boss joins PureTech board

PARIS - Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company.

27 Feb 2015

CORRECTED-Sacked Sanofi boss joins PureTech board

PARIS, Feb 27 - Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company.

27 Feb 2015

Sanofi diabetes drug Toujeo wins EU green light, pricing in focus

LONDON - French drugmaker Sanofi's new Toujeo diabetes drug has been recommended for approval in Europe, two days after being cleared for sale in the United States, regulators said on Friday.

27 Feb 2015

UPDATE 1-Sanofi diabetes drug Toujeo wins EU green light, pricing in focus

* Pricing seen key in determining Toujeo take-up (Adds product details, debate on pricing)

27 Feb 2015

Sanofi diabetes drug Toujeo wins European green light

LONDON, Feb 27 - French drugmaker Sanofi's new Toujeo diabetes drug has been recommended for approval in Europe, two days after being cleared to go on sale in the United States, regulators said on Friday.

27 Feb 2015

Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

- French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult.

26 Feb 2015

UPDATE 2-Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

Feb 26 - French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult.

26 Feb 2015

Sanofi diabetes drug awaits imminent EU green light

LONDON - Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday.

26 Feb 2015

Sanofi diabetes drug awaits imminent EU green light

LONDON, Feb 26 - Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday.

26 Feb 2015

FDA approves Sanofi's diabetes drug Toujeo

- U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.

26 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Finlabo SIM Spa
£7.00
Provider: S&P Capital IQ – STARS Reports
£82.00
Provider: Reuters Investment Profile
£10.00
Provider: Reuters Investment Profile
£10.00
Provider: Thomson Reuters ONE
£0.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks